Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with Rendu-Osler disease.

Date publication

mai 2012

Journal

The Laryngoscope

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DEBRY Christian

Tous les auteurs :
Guldmann R, Dupret A, Nivoix Y, Schultz P, Debry C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/22447341

Résumé

To evaluate the efficacy and safety of bevacizumab administered at a concentration of 50 mg as an intranasal spray in the treatment of epistaxis in patients suffering from Rendu-Osler disease.

Mots clés

Administration, Intranasal, Aerosols, Angiogenesis Inhibitors, administration & dosage, Antibodies, Monoclonal, Humanized, administration & dosage, Bevacizumab, Dose-Response Relationship, Drug, Epistaxis, drug therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Nasal Sprays, Prospective Studies, Quality of Life, Telangiectasia, Hereditary Hemorrhagic, complications, Treatment Outcome, Vascular Endothelial Growth Factor A

Référence

Laryngoscope. 2012 May;122(5):953-5